



Press Release

Lund, Sweden and Cadorago, Italy, June 20, 2018

ImmuneBiotech and Sacco enter strategic manufacturing agreement

ImmuneBiotech AB, a microbiome company developing scientifically proven super-consortia of lactobacilli strains for therapeutic effect, and Sacco S.r.l., one of Europe's leading probiotic manufacturers and suppliers of raw ingredients, are pleased to announce a strategic manufacturing and supply agreement.

Under the terms of the agreement, Sacco will develop manufacturing processes and exclusively produce for the European market the strains in ImmuneBiotech's GutMagnific™, a new scientifically-designed probiotic food supplement for Irritable Bowel Syndrome (IBS), one of the most common gut conditions affecting 15% of the population.

"I'm very pleased to collaborate with Sacco and to have the opportunity to work with their experienced team to produce our first product in their state-of-the-art facilities. Now we will bring the fruits of our 15 years of research experience in immunology and the microbiome into commercial production, starting with GutMagnific™, which will be launched as a food supplement already next year", said Shahram Lavasani, CEO of ImmuneBiotech.

"We are proud and honored to have the chance to cooperate with ImmuneBiotechAB and to help them, by manufacturing their strains, to bring their products to the market and to support their passion for science" said Marco Caspani, General Manager of CSL, a Sacco System company.

About GutMagnific™

GutMagnific™ is scientifically designed to address the underlying causes of IBS using similar pharmacological methods as are used in pharmaceutical drug development, to correct microbial imbalance (dysbiosis), restore disrupted intestinal permeability, and reduce intestinal/distal inflammation. It is a patent pending combination of five proprietary lactobacillus strains and will be sold as a food supplement supported by clinical data. GutMagnific™ has potential applications in several severe and prevalent conditions in addition to IBS, such as diarrhea, antibiotic induced diarrhea, *Clostridium difficile* infection (CDI) and Chronic Fatigue Syndrome (ME/CFS). It has also the ability to target conditions such as leaky gut and small intestine bacterial overgrowth (SIBO).

About ImmuneBiotech AB

ImmuneBiotech discovers and develops novel probiotics for therapeutic effect based on lactic acid bacteria and symbiotic formulations targeting gut microbiota and the immune system. We deliver transformational solutions to modulate the microbiome, heal leaky gut and reduce inflammation to prevent and treat autoimmune and other chronic inflammatory conditions. For more information please visit www.immunebiotech.com.

About Sacco S.r.l.

Sacco, founded in 1934, is one of Europe's leading probiotic manufacturers and supplies raw ingredients, including some of the world's best-selling probiotic strains, to over 2,500 businesses across Europe. Sacco is part of Sacco System, a network of companies that is the new international biotech center for innovation in food, nutraceutical and pharmaceutical products. For more information please visit www.saccosystem.com.

For further information:

ImmuneBiotech AB

Shahram Lavasani, CEO
s.lavasani@immunebiotech.com
+46 707 40 86 61

Sacco S.r.l.

Marco Caspani, General Manager CSL
m.caspani@csllitalia.it
+39 0318866611